BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2017 6:45:23 AM | Browse: 1040 | Download: 1870
 |
Received |
|
2017-01-17 09:47 |
|
Peer-Review Started |
|
2017-01-18 19:37 |
|
To Make the First Decision |
|
2017-02-09 15:03 |
|
Return for Revision |
|
2017-02-14 11:39 |
|
Revised |
|
2017-03-08 14:12 |
|
Second Decision |
|
2017-06-09 05:21 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-06-12 08:34 |
|
Articles in Press |
|
2017-06-12 08:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-07-03 08:45 |
|
Publish the Manuscript Online |
|
2017-07-12 06:45 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety
|
| Manuscript Source |
Invited Conference Manuscripts |
| All Author List |
Nyan L Latt, Beshoy T Yanny, Derenik Gharibian, Rita Gevorkyan and Amandeep K Sahota |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nyan L Latt, MD, Transplant Hepatology Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States. latt.nyan@mayo.edu |
| Key Words |
Hepatitis C; sustained viral response; ledipasvir; cirrhosis; sofosbuvir |
| Core Tip |
We highlight that sustained viral response (SVR) outcomes in patients with their non-cirrhotic status determined by clinical judgment using simple, cheap, non-invasive tests such as platelet count, sonographic finding of spleen size and hepatic morphology, are comparable with those who had specialized tests such as liver biopsy, vibration-controlled transient elastography or specialized serum biomarker test. We also validate the fact that hepatitis C virus (HCV) RNA plays a role in predicting SVR (AUROC = 0.743, 95%CI: 0.66-0.82) with a cutoff value of 2.2 million IU/mL. Significantly higher 98% SVR was observed among HCV RNA < 2.2 million IU/mL, compared to 92% SVR with HCV RNA ≥ 2.2 million IU/mL. |
| Publish Date |
2017-07-12 06:45 |
| Citation |
Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million IU/mL: Single center, real world effectiveness and safety. World J Gastroenterol 2017; 23(26): 4759-4766 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i26/4759.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i26.4759 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
